A comparative proteomic study identified calreticulin and prohibitin up-regulated in adrenocortical carcinomas by Ming-shan Yang et al.
Yang et al. Diagnostic Pathology 2013, 8:58
http://www.diagnosticpathology.org/content/8/1/58RESEARCH Open AccessA comparative proteomic study identified
calreticulin and prohibitin up-regulated in
adrenocortical carcinomas
Ming-shan Yang1*, Huan-sheng Wang1, Bao-sheng Wang1, Wan-hu Li1, Zeng-fen Pang1, Ben-kui Zou1, Xin Zhang1,
Xue-tao Shi1, Dian-bin Mu2, De-xian Zhang2, Yong-sheng Gao2, Xiao-wen Sun3 and Shu-jie Xia3Abstract
Background: Identifying novel tumor biomarkers to develop more effective diagnostic and therapeutic strategies
for patients with ACC is urgently needed. The aim of the study was to compare the proteomic profiles between
adrenocortical carcinomas (ACC) and normal adrenocortical tissues in order to identify novel potential biomarkers
for ACC.
Methods: The protein samples from 12 ACC tissues and their paired adjacent normal adrenocortical tissues were
profiled with two-dimensional electrophoresis; and differentially expressed proteins were identified by mass
spectrometry. Expression patterns of three differently expressed proteins calreticulin, prohibitin and HSP60 in ACC,
adrenocortical adenomas (ACA) and normal adrenocortical tissues were further validated by immunohistochemistry.
Results: In our proteomic study, we identified 20 up-regulated and 9 down-regulated proteins in ACC tissues
compared with paired normal controls. Most of the up-regulated proteins were focused in protein binding and
oxidoreductase activity in Gene Ontology (GO) molecular function classification. By immunohistochemistry, two
biomarkers calreticulin and prohibitin were validated to be overexpressed in ACC compared with adrenocortical
adenomas (ACA) and normal tissues, but also calreticulin overexpression was significantly associated with tumor
stages of ACC.
Conclusion: For the first time, calreticulin and prohibitin were identified to be novel candidate biomarkers for ACC,
and their roles during ACC carcinogenesis and clinical significance deserves further investigation.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1897372598927465
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Adrenocortical carcinomas (ACC) is an extremely rare
malignancy, accounting for 0.2% of cancer deaths annu-
ally in the world [1]. Most of ACC are carcinomatous,
an extremely minor proportion of ACC tumors are char-
acterized by the presence sarcomatous components [2].
Recently, a couple of molecular pathways such as Wnt/
β-catenin signaling have been found to be involved in
the carcinogenesis of ACC [3]. However, for the lack of* Correspondence: sdyangmingshan@163.com
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reproduction in any medium, provided the orearly detection markers and effective treatments, ACC
patients, especially advanced-stage patients still have a
poor prognosis [4].
Several recent studies have identified a panel of novel
biomarkers or potential targets for ACC. For example,
Sbiera et al. [5] found that survivin overexpression was as-
sociated with a poor prognosis for ACC patients, and
targeting survivin might be an interesting new therapeutic
approach for ACC. Gaujoux S, et al. [6] confirmed that
the presence of β-catenin nuclear staining is an indepen-
dent prognostic factor of overall and disease-free survival
in patients with resected primary ACC. Duregon et al. [7]
suggest that detection of steroidogenic factor 1 (SF-1)d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cer. Insulin growth factor type 2 has been demonstrated
consistently overexpressed in ACC, and targeting its re-
ceptor IGF1R has shown encouraging treatment potential
[8]. However, candidate biomarkers for ACC are relatively
limited compared with other cancer types. Therefore,
there is still an urgent need to identify novel tumor bio-
markers to develop more effective diagnostic and thera-
peutic strategies for patients with ACC.
The comparative proteomic strategies provide useful
tools in identifying novel biomarkers for multiple can-
cers. According to our knowledge, until now, there is
still no proteomic study reported on ACC samples. In
this study, we compare the proteomic profiles of ACC
tissues and their paired normal adrenocortical tissues by
two-dimensional electrophoresis (2-DE) and tandem
mass spectrometry. A panel of proteins aberrantly
expressed in ACC tissues were identified, and part of
them were further validated by immunohistochemistry
in a larger cohort of samples.
Materials and methods
Samples
For proteomic research, a total of 12 primary ACC tumor
tissues and their paired adjacent normal adrenocortical
tissues were obtained from patients underwent resective
operation at Shandong Tumor Hospital, China. For it is
hard to obtain normal healthy adrenocortical tissues, we
adopted normal adjacent adrenocortical tissues as a con-
trol of ACC in our proteomic studies. Fresh ACC tissue
(3–5 mm in diameter) were obtained from the core part
of cancer tissues without necrosis, and grossly normal ad-
jacent tissues were taken from the resection margin of
ACC tumors. Resected fresh tissues were first snap-frozen
in liquid nitrogen, and stored at −80°C until use. For im-
munohistochemistry validation study, a total of 39 ACC
and paired normal adrenocortical tissues, and 31 benign
adrenocortical adenomas (ACA) were also obtained from
Shandong Tumor Hospital. All the samples were histolog-
ically confirmed by two independent pathologists (D Mu
and De Zhang). The study was started upon approved by
the ethical committee of our institution, and samples were
obtained with informed consent.
Two dimensional electrophoresis (2-DE)
Frozen ACC and normal adjacent adrenocortical tissues
were first homogenized using a sample grinding kit (GE
Healthcare) with a lysis buffer (7 M urea, thiourea 2 M,
2% CHAPS, 18 mM DTT, 1 mM PMSF, 0.5% IPG buffer
pH3~10NL), and then the extracts were centrifuged at
12,000 g, 4°C, for 1 hr. After the centrifugation, the su-
pernatants were collected for 2-DE analysis. The protein
concentration was determined using a 2D Quant kit
(GE Healthcare).We adopted a “sample pool” strategy in the comparative
proteomic study as described previously [9]. Equal amount
500 μg of proteins extracted from ACC and normal adre-
nocortical tissues were pooled respectively, and diluted
with rehydration buffer (8 M urea, 2% CHAPS, 0.5% IPG
buffer, 40 mM DTT) for isoelectric focusing. After isoelec-
tric focusing, the strips were first equilibrated with
130 mM DTT in equilibration buffer (6 M urea, 30% gly-
cerol, 2% SDS, 50 mM Tris–HCl, pH 8.8), and then with
135 mM iodoacetamide in the same buffer. SDS polyacry-
lamide (SDS-Page) was performed with constant power
(17 W/gel) at 20°C on an Ettan Dalt twelve system
(GE healthcare). After the 2-DE, the gels were stained with
Coomassie blue R350 and images were scanned for
data analysis using Imagemaster 5.0 software package
(GE healthcare).
In-gel digestion and mass spectrometry identification
The gel pieces were first destained with 25 mM
NH4CO3/50% ACN for 30 min, and dehydrated in 100%
ACN for 10 min, and were then digested in 20 ng/μL se-
quencing grade-modified trypsin (Promega) overnight at
37°C. After extracted with 5% TFA/50% ACN, the pep-
tides were resuspended in 3 μL of 0.1% TFA for mass
spectrometry analysis. Protein identification was per-
formed on 4700 Proteomic Analyzer MALDI-TOF-TOF
mass spectrometer (Applied Biosystems) in a reflective
mode. All mass spectrometry data were searched using
the MASCOT search engine against a human subset of
the Swiss-Prot database.
Immunohistochemistry
Three proteins (calreticulin, prohibitin and HSP60) up-
regulated in ACC identified in the proteomic study were
selected for validation in an independent set of samples
including 39 ACC, 31 ACA, and 39 normal adrenocorti-
cal tissues by immunohistochemistry (IHC). Briefly, after
rehydration and deparaffinization, paraffin-embedded
tissue slides were processed for antigen retrieval using
heating in citrate buffer, and immunohistochemically
stained with the rabbit polyclonal antibodies against hu-
man calreticulin (1:150 dilution; PTG-Lab) and prohibitin
(1:150 dilution; PTG-Lab) and heat shock protein 60
(HSP60) (1:100 dilution; PTG-Lab). All these antibodies
were widely used in IHC staining, and their specificity has
been confirmed in many previous studies. Visualization
was performed using a SP kit (Maixin-Bio, Fujian, China).
For the negative controls, the primary antibody was re-
placed by rabbit IgG.
A semi-quantitative H score method was used to evalu-
ate the results of IHC as described previously within
minor modification [10]. Staining intensity was quantified
using the image analysis program Leica Qwin V3, and
were graded to four-scale (0–3), while the percentages of
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cells; 1, 1%–33% positive cells; 2, 34%–66%; and 3,
67%–100%). H score (ranging from 0 to 9) was calculated
by multiplying staining intensity and the percentage of
positive cells. The median H-score was used as a cut-off
for classify low (< median H-score) and high (≥ median
H-score) expression of each markers.
Statistics
For proteomic study, spots with intensity changes
greater than 2.0-fold were considered as differently
expressed spots, and were excised from gels for mass
spectrometry analysis. Gene Ontolgoy (GO) analysis was
performed using MAS (Molecular Annotation System)
2.0 software (CapitalBio, China). For immunohistoche-
mical results, the difference in H scores of ACC, ACA,
and normal controls were compared with Mann–Whitney
t test, and the correlation between biomarkers with the
clinicopathological traits of ACC patients was eva-
luated with Chi-square or Student t test as appropriate.
P value less than 0.05 was considered statistically
significant.
Results
Comparative proteomic profiling between ACC and
adjacent normal adrenocortical tissues
The 2-DE analyses were repeated in three replicas to
guarantee the reproducibility of the results. As seen in
Figure 1, representative gel images were selected for
comparative proteomic analyses of ACC and their nor-
mal controls. According to the criteria established, spots
with two fold variation between the two groups were de-
fined as differentially expressed proteins. A total of 29Figure 1 Representative images of two-dimensional electrophoresis (
adjacent normal adrenocortical tissues (B).differentially expressed spots were successfully identified
by mass spectrometry. Twenty proteins were identified
as being up-regulated in ACC samples, compared with
their corresponding proteins in normal adrenocortical
tissues, while 9 proteins were identified to be down-
regulated. The details of differently expressed proteins
were summarized in Table 1.
Gene Ontology (GO) analysis on the differently expressed
proteins identified in proteomic study
As seen in Table 2, GO analysis on molecular function
revealed that up-regulated proteins in ACC samples
were enriched most in protein binding (Secretogranin-1,
prelamin A/C, keratin 10, actin cytoplasmic 1, glutathione
S-transferase P, elongation factor 1-beta, peroxiredoxin-1)
and oxidoreductase activity (retinal dehydrogenase 1,
peroxiredoxin-1, peroxiredoxin-2, aflatoxin B1 aldehyde
reductase member 3).
Expression of calreticulin, prohibitin and HSP60 in ACC,
ACA and normal adrenocortical tissues by
immunohistochemistry
Three differentially expressed proteins, calreticulin,
prohibitin and heat shock protein 60 (HSP60), which
had not been reported in previous studies on ACC sam-
ples, were selected to be validated in a larger size of
samples by immunishotchemistry. As seen in Figure 2,
the expression levels (H score) of calreticulin, prohibitin
and HSP60 were significantly higher in ACC samples
than those in normal adrenocortical tissues, which are
consistent with the findings in proteomic study. Fur-
thermore, ACC tumors also demonstrated a higher2-DE). 2-DE maps of adrenocortical carcinomas (A) and their paired













Secretogranin-1 P05060 78343 5.02 24 245 39 2.3
Retinal dehydrogenase 1 P00352 55454 6.3 9 66 24 3.1
Prelamin-A/C P02545 74379 6.57 26 234 37 2.2
Transitional endoplasmic reticulum
ATPase
P55072 89949 5.14 31 383 45 4.1
Keratin, type I cytoskeletal 10 P13645 59020 5.13 11 84 20 2.8
Prohibitin P35232 29843 5.57 10 148 51 3.8
Transgelin-2 P37802 22548 8.41 8 85 49 2.2
Selenium-binding protein 1 Q13228 52928 5.93 8 82 23 2.1
Actin, cytoplasmic 1 Q96HG5 42052 5.29 11 93 34 4.3
Glutathione S-transferase P P09211 23569 5.43 12 139 60 2.7
Peroxiredoxin-2 P32119 22049 5.66 10 153 47 2.4
Rho GDP-dissociation inhibitor 1 P52565 23250 5.02 11 122 45 2.3
Elongation factor 1-beta P24534 24919 4.5 10 113 46 3.3
Peroxiredoxin-1 Q06830 22324 8.27 11 165 62 3.2
14-3-3 protein epsilon Q7M4R4 29326 4.63 11 111 41 5.1
60 kDa heat shock protein P10809 61187 5.7 18 222 40 4.3
ATP synthase subunit d,
mitochondrial
O75947 18537 5.21 9 119 59 3.8
Retinal dehydrogenase 1 P00352 55454 6.3 16 189 41 3.6
Calreticulin P27797 48283 4.29 13 180 43 5.2
Aflatoxin B1 aldehyde reductase
member 3
O95154 37582 6.67 15 148 48 2.6
T-complex protein 1 subunit beta P78371 57794 6.01 15 140 43 −3.2
Elongation factor Tu, mitochondrial P49411 49852 7.26 26 287 61 −4.1
Protein disulfide-isomerase P07237 57479 4.76 17 171 37 −2.2
Vimentin Q8N850 53676 5.06 12 85 33 −2.0
Serum albumin Q9P157 71317 5.92 27 319 54 −3.7
Peroxiredoxin-2 P32119 22049 5.66 9 152 43 −2.8
Tropomyosin alpha-4 chain Q9UCS3 28619 4.67 10 130 34 −2.5
Proteasome subunit beta type-2 P49721 22993 6.51 8 106 49 −3.3
Fibrinogen gamma chain Q9UC63 52106 5.37 8 86 28 −3.3
Table 2 Gene Ontology (GO) analysis on up-regulated proteins in proteomics study
GO term Count p-value Gene symbol
GO:0005515 protein binding 7 2.79E-08 CHGB;LMNA;KRT10;ACTB;GSTP1;EEF1B2;PRDX1
GO:0016491 oxidoreductase activity 4 2.79E-08 ALDH1A1;PRDX2;PRDX1;AKR7A3
GO:0051087 chaperone binding 2 4.17E-07 HSPD1;CALR
GO:0016887 ATPase activity 3 4.52E-07 VCP;HSPD1;ATP5H
GO:0051082 unfolded protein binding 2 1.33E-05 HSPD1;CALR
GO:0005524 ATP binding 3 3.47E-05 VCP;ACTB;HSPD1
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Figure 2 Representative images of immunohistochemical results. Expression of calreticulin, prohibitin and HSP60 in adrenocortical
carcinomas (ACC), adrenocortical adenomas (ACA) and normal tissues (N) (A). Calreticulin and prohibitin but not HSP60 were overexpressed in
ACC compared with adrenocortical adenomas (ACA) and normal tissues (B).
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tumors, but the expression of HSP60 showed no signifi-
cant difference between malignant and benign adreno-
cortical tumors. Negative staining with nonspecific
rabbit IgG control was documented for each experiment
(data not shown).Association of calreticulin and prohibitin expression with
clinicopathological characteristics in ACC
According to the criteria for IHC evaluation, the median
H-score of 6 was set as the cut-point to delineate low
and high expression for calreticulin and prohibitin. The
relationship between calreticulin and prohibitin expre-
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mors was analyzed. As seen Table 3, no significant differ-
ence was observed between calreticulin and prohibitin
expression with all the chinicopathological characteristics
of ACC tumors, except that calreticulin overexpression
was significantly associated with stages in ACC samples.
High calreticulin expression was seen more frequently in
advanced-stage ACC tumors than in early-stage cases
(65.0% vs. 31.6%, P = 0.037).
Discussion
In this study, for the first time, we performed a 2-DE-based
proteomic study to compare the protein profiling of
ACC and normal adrenocortical tissues. A panel of pro-
tein markers were identified to be differently expressed.
For only a few samples could be included in traditional
proteomic studies, we adopted a “sample pool” strategy
to increase the sample size. This strategy could also de-
crease the sample heterogeneity in some extent. To va-
lidate the results of proteomic analysis, we further
validate three biomarkers calreticulin, prohibitin and
HSP60 in a larger size of samples by immuno-
histochemestry. These proteins were selected for the
following reasons: first, these biomarkers have a rela-







Age (y, Mean ± SD) 45 ± 17.4 37 ± 14
Gender
Male 18 8 10
Female 21 11 10
Tumor
location
Left 17 7 10
Right 19 10 9
Bilateral 3 2 1
Primary tumor size
< 5.0 cm 5 2 3
5.0 – 10.0 cm 28 16 12
> 10.0 cm 6 1 5
ENSAT stage
I- II 20 13 7
III- IV 19 6 13
Hormonal secretory status
Non-functioning tumor 21 12 9
Functioning tumor 18 7 11normal adrenocortical tissues; secondly, previous stu-
dies have indicated that these genes are involved in the
malignant progression of multiple cancers, but have not
been evaluated in ACC; third, commercial antibodies
for immunohistochemistry are available.
Consistent with our proteomic findings, we confirmed
calreticulin, prohibitin and HSP60 overexpressed in
ACC tumors than normal adrenocortical tissues. It has
been suggested that the protein profiling of benign tu-
mors partly resemble their malignant counterparts [11].
A candidate marker elevated in both ACC and ACA
would lower their specificity in ACC diagnosis. There-
fore, we further compared the expression of calreticulin,
prohibitin and HSP60 in ACA and ACC. We found that
HSP60 was overexpressed in both ACC and ACA, com-
pared with their normal controls, which would lower its
further utility as a candidate biomarker for ACC. Diffe-
rent from HSP60, ACC tissues had significantly higher
expression levels of calreticulin and prohibitin than
ACA, supporting their utility as specific biomarkers for
ACC tumors.
Calreticulin was first identified as a Ca2+ binding pro-
tein, and has been implicated in many cellular functions
and pathophysiological process such as cell adhesion,
autoimmunity and heat shock [12,13]. Elevated expression
of calreticulin has been reported in multiple cancers,ssion status with clinical charateristics in ACC
P
Prohibitin expression
P20) Low (n = 18) High (n = 21)
.5 0.129 43 ± 18.6 39 ± 14.4 0.486
0.621 8 10 0.843
10 11




0.181 14 14 0.454
3 3
0.037 8 12 0.429
10 9
0.256 11 10 0.399
7 11
Yang et al. Diagnostic Pathology 2013, 8:58 Page 7 of 8
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seems to be induced by cellular stress from cancers
[14]. Our results indicated that calreticulin correlated
to tumor stage of ACC in clinical samples. However,
the exact mechanisms for its increases in ACC are as
yet undetermined.
Prohibitin has been shown to localize to mitochondria,
and has been identified to be up-regulated in many can-
cers in previous studies [15]. However, experimental data
about its role in tumorigenesis is conflicting. Several stu-
dies have suggested that prohibitin effects as a tumor
suppressor [16], while other data indicated that
prohibitin is required for the activation of several central
signaling pathways related to carcinogenesis such as
RAS-induced RAF-MEK-ERK activation [17]. Our fin-
dings supported that prohibitin upregualted in ACC tu-
mors and its roles in ACC carcinogenesis deserves
further investigation.
Except above three markers, we also identified other 17
up-regulated proteins in ACC, most of which (such as
transitional endoplasmic reticulum ATPase and 14-3-3
protein epsilon) have been demonstrated to be involved in
cancer carcinogenesis in other cancers in previous studies
[18-20], but have not been reported to be associated with
ACC. Therefore, these proteins might also be novel poten-
tial candidate markers for ACC, and deserves further in-
vestigation in the future.
Conclusions
In this proteomic study, we identified and validated
calreticulin and prohibitin overexpressed in ACC sam-
ples compared with their normal and benign counter-
parts, suggesting that these two markers are novel
potential candidate biomarkers for ACCs. We proposed
that the molecular mechanisms of calreticulin and
prohibitin during ACC carcinogenesis also deserve fur-
ther investigation in the future.
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